GoodRx (GDRX) Stock Forecast, Price Target & Predictions
GDRX Stock Forecast
GoodRx stock forecast is as follows: an average price target of $14.57 (represents a 148.21% upside from GDRX’s last price of $5.87) and a rating consensus of 'Buy', based on 18 wall street analysts offering a 1-year stock forecast.
GDRX Price Target
GDRX Analyst Ratings
GoodRx Price Target by Analyst
Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
---|---|---|---|---|---|---|
Jun 10, 2024 | Craig Hettenbach | Morgan Stanley | $9.50 | $8.55 | 11.11% | 61.84% |
May 23, 2024 | Mark Mahaney | RBC Capital | $10.00 | $7.20 | 38.89% | 70.36% |
May 16, 2024 | Stephanie Davis | Barclays | $9.00 | $8.06 | 11.66% | 53.32% |
May 16, 2024 | Aaron Kessler | Raymond James | $10.00 | $7.27 | 37.55% | 70.36% |
Apr 10, 2024 | Scott Schoenhaus | BOCOM International Holdings Company | $9.00 | $6.92 | 30.06% | 53.32% |
Apr 10, 2024 | Scott Schoenhaus | KeyBanc | $9.00 | $6.74 | 33.53% | 53.32% |
Mar 25, 2024 | Stan Berenshteyn | Wells Fargo | $10.00 | $7.23 | 38.39% | 70.36% |
Nov 13, 2023 | Eric Sheridan | Goldman Sachs | $3.00 | $4.73 | -36.58% | -48.89% |
Dec 01, 2022 | - | Citigroup | $7.00 | $4.36 | 60.55% | 19.25% |
Aug 09, 2022 | Steve Valiquette | Barclays | $13.00 | $7.76 | 67.53% | 121.47% |
GoodRx Price Target by Period
1M | 3M | 12M | |
---|---|---|---|
# Anlaysts | - | - | 8 |
Avg Price Target | - | - | $8.69 |
Last Closing Price | $5.87 | $5.87 | $5.87 |
Upside/Downside | -100.00% | -100.00% | 48.04% |
Analyst Ratings Upgrades/Downgrades
Date | Company | Previous Rating | New Rating | Rating Change |
---|---|---|---|---|
Oct 01, 2024 | Cowen & Co. | Buy | Buy | Hold |
Aug 16, 2024 | UBS | Buy | Buy | Hold |
Aug 09, 2024 | Raymond James | Outperform | Strong Buy | Upgrade |
Jun 10, 2024 | Morgan Stanley | Equal-Weight | Equal-Weight | Hold |
May 23, 2024 | RBC Capital | Sector Perform | Outperform | Upgrade |
May 16, 2024 | Barclays | Overweight | Overweight | Hold |
May 16, 2024 | Wells Fargo | Sector Perform | Sector Perform | Hold |
May 16, 2024 | UBS | Underperform | Underperform | Hold |
May 16, 2024 | KeyBanc | Overweight | Overweight | Hold |
May 16, 2024 | Raymond James | Strong Buy | Outperform | Upgrade |
GoodRx Financial Forecast
GoodRx Revenue Forecast
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | - | - | - | - | - | - | - | - | - | - | - | - | $196.64M | $179.96M | $189.68M | $183.99M | $184.11M | $187.32M | $191.80M | $203.33M | $213.26M | $195.10M | $176.63M | $160.43M | $153.54M | $140.45M |
Avg Forecast | $253.09M | $241.08M | $242.77M | $237.76M | $229.71M | $219.31M | $218.71M | $212.12M | $206.25M | $195.66M | $200.47M | $196.11M | $194.30M | $188.52M | $186.84M | $182.09M | $178.50M | $185.04M | $184.71M | $200.45M | $217.46M | $194.78M | $174.58M | $160.62M | $147.82M | $135.07M |
High Forecast | $253.09M | $241.08M | $242.77M | $237.76M | $229.71M | $219.31M | $218.71M | $212.12M | $206.25M | $196.74M | $200.47M | $196.11M | $194.74M | $188.53M | $186.84M | $182.09M | $178.50M | $185.04M | $184.71M | $200.45M | $217.46M | $194.78M | $174.58M | $160.62M | $147.82M | $135.07M |
Low Forecast | $253.09M | $241.08M | $242.77M | $237.76M | $229.71M | $219.31M | $218.71M | $212.12M | $206.25M | $195.24M | $200.47M | $196.11M | $193.12M | $188.51M | $186.84M | $182.09M | $178.50M | $185.04M | $184.71M | $200.45M | $217.46M | $194.78M | $174.58M | $160.62M | $147.82M | $135.07M |
# Analysts | 10 | 7 | 5 | 5 | 8 | 5 | 4 | 4 | 8 | 11 | 5 | 4 | 8 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 4 | 5 | 4 | 5 | 4 |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.01% | 0.95% | 1.02% | 1.01% | 1.03% | 1.01% | 1.04% | 1.01% | 0.98% | 1.00% | 1.01% | 1.00% | 1.04% | 1.04% |
GoodRx EBITDA Forecast
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 10 | 7 | 5 | 5 | 8 | 5 | 4 | 4 | 8 | 11 | 5 | 4 | 8 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 4 | 5 | 4 | 5 | 4 |
EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | $1.68M | $-12.09M | $42.22M | $31.67M | $22.71M | $1.16M | $10.13M | $31.19M | $22.42M | $17.17M | $8.03M | $379.00K | $-295.01M | $-56.50M |
Avg Forecast | $14.63M | $13.93M | $14.03M | $13.74M | $13.28M | $12.67M | $12.64M | $12.26M | $11.92M | $11.31M | $11.59M | $37.43M | $11.23M | $10.90M | $10.80M | $29.59M | $31.20M | $10.69M | $10.67M | $23.39M | $12.57M | $11.26M | $10.09M | $379.00K | $8.54M | $-49.44M |
High Forecast | $14.63M | $13.93M | $14.03M | $13.74M | $13.28M | $12.67M | $12.64M | $12.26M | $11.92M | $11.37M | $11.59M | $44.91M | $11.25M | $10.90M | $10.80M | $35.51M | $37.44M | $10.69M | $10.67M | $28.07M | $12.57M | $11.26M | $10.09M | $454.80K | $8.54M | $-39.55M |
Low Forecast | $14.63M | $13.93M | $14.03M | $13.74M | $13.28M | $12.67M | $12.64M | $12.26M | $11.92M | $11.28M | $11.59M | $29.94M | $11.16M | $10.89M | $10.80M | $23.67M | $24.96M | $10.69M | $10.67M | $18.71M | $12.57M | $11.26M | $10.09M | $303.20K | $8.54M | $-59.33M |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.15% | -1.11% | 3.91% | 1.07% | 0.73% | 0.11% | 0.95% | 1.33% | 1.78% | 1.53% | 0.80% | 1.00% | -34.53% | 1.14% |
GoodRx Net Income Forecast
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 10 | 7 | 5 | 5 | 8 | 5 | 4 | 4 | 8 | 11 | 5 | 4 | 8 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 4 | 5 | 4 | 5 | 4 |
Net Income | - | - | - | - | - | - | - | - | - | - | - | - | $-25.87M | $-38.49M | $58.79M | $-3.29M | $-1.97M | $-41.73M | $-1.42M | $12.29M | $-39.91M | $-18.07M | $31.06M | $1.67M | $-298.27M | $-50.03M |
Avg Forecast | $56.98M | $52.84M | $52.75M | $49.28M | $49.48M | $45.21M | $42.54M | $38.83M | $36.27M | $33.45M | $33.46M | $14.75M | $25.97M | $22.35M | $23.29M | $11.66M | $-55.54M | $16.33M | $15.17M | $9.22M | $38.04M | $33.53M | $30.31M | $1.67M | $25.10M | $-43.78M |
High Forecast | $56.98M | $52.84M | $52.75M | $49.28M | $49.48M | $45.21M | $42.54M | $38.83M | $36.27M | $37.17M | $34.22M | $17.70M | $32.46M | $22.35M | $23.29M | $14.00M | $-44.43M | $16.33M | $15.17M | $11.06M | $38.04M | $33.53M | $30.31M | $2.00M | $25.10M | $-35.02M |
Low Forecast | $56.98M | $52.84M | $52.75M | $49.28M | $49.48M | $45.21M | $42.54M | $38.83M | $36.27M | $29.73M | $32.69M | $11.80M | $19.48M | $22.35M | $23.29M | $9.33M | $-66.65M | $16.33M | $15.17M | $7.38M | $38.04M | $33.53M | $30.31M | $1.33M | $25.10M | $-52.53M |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | -1.00% | -1.72% | 2.52% | -0.28% | 0.04% | -2.56% | -0.09% | 1.33% | -1.05% | -0.54% | 1.02% | 1.00% | -11.88% | 1.14% |
GoodRx SG&A Forecast
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 10 | 7 | 5 | 5 | 8 | 5 | 4 | 4 | 8 | 11 | 5 | 4 | 8 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 4 | 5 | 4 | 5 | 4 |
SG&A | - | - | - | - | - | - | - | - | - | - | - | - | $124.12M | $126.93M | $107.65M | $108.14M | $112.71M | $135.76M | $129.08M | $124.87M | $141.87M | $131.60M | $127.96M | $123.48M | $415.69M | $173.59M |
Avg Forecast | $186.35M | $177.51M | $178.75M | $175.06M | $169.13M | $161.47M | $161.04M | $156.18M | $151.86M | $144.06M | $147.60M | $149.87M | $143.06M | $138.81M | $137.57M | $118.47M | $131.43M | $136.24M | $136.00M | $93.65M | $160.11M | $143.42M | $128.54M | $123.48M | $108.84M | $99.45M |
High Forecast | $186.35M | $177.51M | $178.75M | $175.06M | $169.13M | $161.47M | $161.04M | $156.18M | $151.86M | $144.86M | $147.60M | $179.84M | $143.39M | $138.82M | $137.57M | $142.17M | $131.43M | $136.24M | $136.00M | $112.39M | $160.11M | $143.42M | $128.54M | $148.18M | $108.84M | $99.45M |
Low Forecast | $186.35M | $177.51M | $178.75M | $175.06M | $169.13M | $161.47M | $161.04M | $156.18M | $151.86M | $143.75M | $147.60M | $119.89M | $142.19M | $138.80M | $137.57M | $94.78M | $131.43M | $136.24M | $136.00M | $74.92M | $160.11M | $143.42M | $128.54M | $98.78M | $108.84M | $99.45M |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.87% | 0.91% | 0.78% | 0.91% | 0.86% | 1.00% | 0.95% | 1.33% | 0.89% | 0.92% | 1.00% | 1.00% | 3.82% | 1.75% |
GoodRx EPS Forecast
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 10 | 7 | 5 | 5 | 8 | 5 | 4 | 4 | 8 | 11 | 5 | 4 | 8 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 4 | 5 | 4 | 5 | 4 |
EPS | - | - | - | - | - | - | - | - | - | - | - | - | $-0.06 | $-0.09 | $0.14 | $-0.01 | $-0.00 | $-0.10 | $-0.00 | $0.03 | $-0.10 | $-0.04 | $0.08 | - | $-0.74 | $-0.21 |
Avg Forecast | $0.15 | $0.14 | $0.14 | $0.13 | $0.13 | $0.12 | $0.11 | $0.10 | $0.09 | $0.09 | $0.09 | $0.08 | $0.07 | $0.06 | $0.06 | $0.06 | $0.05 | $0.04 | $0.04 | $0.08 | $0.10 | $0.09 | $0.08 | $0.07 | $0.07 | $0.08 |
High Forecast | $0.15 | $0.14 | $0.14 | $0.13 | $0.13 | $0.12 | $0.11 | $0.10 | $0.09 | $0.10 | $0.09 | $0.08 | $0.08 | $0.06 | $0.06 | $0.06 | $0.05 | $0.04 | $0.04 | $0.08 | $0.10 | $0.09 | $0.08 | $0.07 | $0.07 | $0.08 |
Low Forecast | $0.15 | $0.14 | $0.14 | $0.13 | $0.13 | $0.12 | $0.11 | $0.10 | $0.09 | $0.08 | $0.08 | $0.07 | $0.05 | $0.06 | $0.06 | $0.06 | $0.05 | $0.04 | $0.04 | $0.08 | $0.10 | $0.09 | $0.08 | $0.07 | $0.07 | $0.08 |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | -0.95% | -1.60% | 2.31% | -0.14% | -0.10% | -2.36% | -0.09% | 0.37% | -0.98% | -0.46% | 1.02% | 0.06% | -11.34% | -2.77% |
GoodRx Peer Comparison by Price Target
Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
---|---|---|---|---|---|
TDOC | Teladoc Health | $8.87 | $50.87 | 473.51% | Hold |
ACCD | Accolade | $3.15 | $14.81 | 370.16% | Buy |
HCAT | Health Catalyst | $7.68 | $29.25 | 280.86% | Buy |
GDRX | GoodRx | $5.87 | $14.57 | 148.21% | Buy |
DH | Definitive Healthcare | $4.08 | $9.50 | 132.84% | Hold |
SLP | Simulations Plus | $27.49 | $56.00 | 103.71% | Buy |
CERT | Certara | $10.25 | $20.60 | 100.98% | Buy |
PGNY | Progyny | $15.15 | $29.00 | 91.42% | Hold |
EVH | Evolent Health | $23.36 | $43.00 | 84.08% | Buy |
TXG | 10x Genomics | $16.78 | $30.20 | 79.98% | Hold |
PRVA | Privia Health Group | $19.22 | $33.82 | 75.96% | Buy |
SDGR | Schrödinger | $18.24 | $28.67 | 57.18% | Buy |
VEEV | Veeva Systems | $212.53 | $229.71 | 8.08% | Buy |
GEHC | GE HealthCare | $86.99 | $93.40 | 7.37% | Buy |
HSTM | HealthStream | $29.17 | $29.00 | -0.58% | Buy |
DOCS | Doximity | $41.82 | $39.29 | -6.05% | Buy |
AMWL | American Well | $9.12 | $8.40 | -7.89% | Hold |
TALK | Talkspace | $3.13 | $2.50 | -20.13% | Hold |
GDRX Forecast FAQ
Is GoodRx a good buy?
Yes, according to 18 Wall Street analysts, GoodRx (GDRX) is considered a 'Buy'. The rating consensus is based on 1 'Strong Buy' and 9 'Buy' recommendations, accounting for 55.56% of GDRX's total ratings.
What is GDRX's price target?
GoodRx (GDRX) average price target is $14.57 with a range of $3 to $45, implying a 148.21% from its last price of $5.87. The data is based on 18 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will GoodRx stock go up soon?
According to Wall Street analysts' prediction for GDRX stock, the company can go up by 148.21% (from the last price of $5.87 to the average price target of $14.57), up by 666.61% based on the highest stock price target, and down by -48.89% based on the lowest stock price target.
Can GoodRx stock reach $9?
GDRX's average twelve months analyst stock price target of $14.57 supports the claim that GoodRx can reach $9 in the near future.
What are GoodRx's analysts' financial forecasts?
GoodRx's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $879.84M (high $879.84M, low $879.84M), average EBITDA is $50.85M (high $50.85M, low $50.85M), average net income is $176.06M (high $176.06M, low $176.06M), average SG&A $647.82M (high $647.82M, low $647.82M), and average EPS is $0.458 (high $0.458, low $0.458). GDRX's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $974.7M (high $974.7M, low $974.7M), average EBITDA is $56.33M (high $56.33M, low $56.33M), average net income is $211.84M (high $211.84M, low $211.84M), average SG&A $717.66M (high $717.66M, low $717.66M), and average EPS is $0.551 (high $0.551, low $0.551).
Did the GDRX's actual financial results beat the analysts' financial forecasts?
Based on GoodRx's last annual report (Dec 2023), the company's revenue was $750.26M, which missed the average analysts forecast of $751.76M by -0.20%. Apple's EBITDA was $-4.632M, missing the average prediction of $62.51M by -107.41%. The company's net income was $-102M, missing the average estimation of $83.27M by -222.82%. Apple's SG&A was $466.84M, missing the average forecast of $537.92M by -13.21%. Lastly, the company's EPS was $-0.25, missing the average prediction of $0.242 by -203.29%. In terms of the last quarterly report (Dec 2023), GoodRx's revenue was $196.64M, beating the average analysts' forecast of $194.3M by 1.21%. The company's EBITDA was $1.68M, missing the average prediction of $11.23M by -85.00%. GoodRx's net income was $-25.869M, missing the average estimation of $25.97M by -199.61%. The company's SG&A was $124.12M, missing the average forecast of $143.06M by -13.24%. Lastly, the company's EPS was $-0.0642, missing the average prediction of $0.0675 by -195.11%